Data4 impact group discussions
Download as PPTX, PDF1 like163 views
The document outlines a discussion held on May 28, 2019, regarding the relevance and practical utility of metrics produced by Data4Impact, specifically aimed at answering the needs of funders and policymakers. It details various indicators at input, throughput, academic, economic, and societal health impact levels, evaluating their effectiveness and convincingness. Data4Impact is funded by the EU's Horizon 2020 program and aims to measure the impact of research and innovation activities.
Data4 impact group discussions
- 1. Group discussions Ghent, 28 May 2019
- 2. Questions for the discussion: 1. Relevance/added value of metrics produced by Data4Impact: are these metrics answering the questions that funders and policymakers have? 2. Utility/practicality of the indicators: do the indicators bring new value compared to what is currently available? 3. Which results/indicators are most/least convincing? Why?
- 3. Key Data4Impact indicators Level Indicator Description 1. Input level indicators 1.1. Funding volume Monetary expenditure on R&I activities 2. Throughpu t level indicators 2.1. Publications Number of publications produced by programme/funder cited in patents Number of highly cited publications in patents 2.2. Patents Number of patents produced 2.3. Innovation outputs produced by EU FPs projects Number of health-specific innovation outputs produced in projects funded by the EU Framework Programmes 2.4. New companies Number of new companies/start-ups created in the EU Framework Programmes 2.5. Innovation outputs produced by companies participating in R&I activities Number of product innovations; or process, service or other innovations announced by companies 2.6. Innovation activities carried out by companies participating in R&I activities Number of licensing agreements; or cases of acquisitions; or cases of private funding attracted; or cases of public funding attracted by companies; or cases of newly CE-marked medical devices or technologies 3. Academic impact 3.1. Funding priorities Topic size in PubMed (absolute and normalised) Distribution of topics per funder (normalised) Distribution of funders per topic (absolute) 3.2. Timeliness of research performed Rate of topic growth between 2012-2018 compared to 2005-2011 Share of funding allocated to top-10% fastest growing topics 3.3. Funding exclusivity Share of funding allocated to top-10% smallest research topics by size (i.e. investment in small-niche topics) Number of funders per topic whose output share exceeds 3% globally Share of funding allocated to research topics with less than 5 funders whose share exceeds the 3% mark (i.e. investment in topics where few other funders invest) 3.4. Technological value/significance of patents Analysis of the extent to which commonly patent forward citations (i.e. citations a patent receives from subsequent patent filings) are used 4. Economic impact 4.1. Economic and innovation performance of companies Estimated share of enterprises with evidence of innovation activities Estimated share of highly innovative enterprises Estimated share of enterprises with evidence of licensing activities (incl. patent/trademark license agreements) Estimated share of enterprises involved in activities related to acquisitions Estimated share of enterprises with evidence of private investment/capital attracted 4.2. Continuity of innovation activities Estimated overlap between project activities in FP7 & identified company innovations Number of newly CE-marked devices and medical technologies that could be directly linked to R&I activities in the EU Framework Programmes 5. Societal/ health impact 5.1. Impact on public health Citations of publications in clinical guidelines 5.2. Societal awareness/relevance of research Rank of research topic based on number of news articles, blogs, posts, tweets, etc. discussing a given topic 5.3. Congruence of research funding with societal priorities Rank similarity of most discussed research topics versus actual spending in the topics 5.4. Newly launched medicines and medicinal products Number of human medicinal products or orphan medicines that could be directly linked to R&I activities in the EU Framework Programmes Strength of link based on the number of mentions of product names and their active substances in EC monitoring data
- 4. Data4Impact has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 770531. Thank you for your attention! Data4Impact Consortium Visit out website: www.data4impact.eu Follow us on Twitter and SlideShare: @Data4Impact